Drug Index


Mechanism :

There are three common forms of artemisinin. The water-soluble form is called artesunate. It is the most active and the least toxic within the body. Artemether is the lipid soluble form. It has the longest life but also the most toxic in high dosage which is seldom needed. The biggest advantage of artemether is that it can cross the blood brain barrier. Artemisinin is the active parent compound of the plant. Its half-life is intermediate. It is also very safe and can cross the blood-brain barrier. Artemisinin has been shown to work through oxygen and carbon based free radical mechanisms. Artemether has been combined with lumefantrine for use as combination therapy orally.

Indication :

  • Malaria

Contraindications :

First trimester of pregnancy.

Dosing :

3.2 mg/kg/IM loading dose followed by 1.6 mg/kg/IM after 24 hours & then 1.6 mg/kg/M 12 hourly till the child can eat orally. Then shift to oral therapy.
Artemether + Lumefantrine (Available as 20 mg of artemether + 120 mg lumefantrine FDC or 40 mg of artemether + 240 mg lumefantrine): oral therapy for 3 days.
5-14 kg: 20 mg of artemether + 120 mg of lumefantrine BID.
15-24 kg: 40 mg of artemether + 240 mg of lumefantrine BID.
25-34 kg: 60 mg of artemether + 360 mg of lumefantrine BID.
≥35 kg: 80 mg of artemether + 480 mg of lumefantrine BID.

Adverse Effect :

Gastrointestinal disturbances, dizziness, tinnitus and prolongation of QT interval.

Interaction :

Quinidine and halofantrine: Caution in concurrent usage with drugs that prolong QT interval.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnknown dialysability. Dose as in GFR<10 mL/min
HDUnknown dialysability. Dose as in GFR<10 mL/min
HDF/High fluxUnknown dialysability. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as in normal renal function

Hepatic Dose :

Mild to moderate hepatic impairment: Dosage adjustments are not recommended.
Severe hepatic impairment: Use with caution.
12/21/2023 02:24:30 Artemether
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0